INDACATEROL FUMARATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H28N2O3.C4H4O4
Molecular Weight	508.5629
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C\C(O)=O.CCC1=CC2=C(CC(C2)NC[C@H](O)C3=CC=C(O)C4=C3C=CC(=O)N4)C=C1CC

InChI

InChIKey=IREJFXIHXRZFER-XRQUGHPZSA-N

InChI=1S/C24H28N2O3.C4H4O4/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;5-3(6)1-2-4(7)8/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1-2H,(H,5,6)(H,7,8)/b;2-1+/t22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C24H28N2O3
Molecular Weight	392.4907
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Beta-2 adrenergic receptor 203 Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20402514	Agonist 2678	76.0 nM [Ki]
Beta-1 adrenergic receptor 158 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20655218	Agonist 2678	91.4 nM [Ki]
Beta-2 adrenergic receptor 203 Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20402514	Agonist 2678	76.0 nM [Ki]
Beta-1 adrenergic receptor 158 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20655218	Agonist 2678	91.4 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf	Primary		Approved 8429	ARCAPTA NEOHALER Approved Use UTIBRONTM NEOHALER® is a combination of indacaterol and glycopyrrolate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important Limitations of Use: UTIBRON NEOHALER is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions (5.1, 5.2) Launch Date 1.30947835E12
Airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf	Primary		Approved 8429	ARCAPTA Approved Use INDICATIONS AND USAGE. ARCAPTA NEOHALER is a long-acting beta2-adrenergic agonist indicated for: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important limitations: ARCAPTA NEOHALER is NOT indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ARCAPTA NEOHALER is NOT indicated for asthma. Launch Date 1.29427204E12

C_max

Value	Dose	Co-administered	Analyte	Population
528 pg/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	110 μg 1 times / day steady-state, respiratory dose: 110 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: GLYCOPYRROLATE	GLYCOPYRROLATE	INDACATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
339 pg/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	110 μg single, respiratory dose: 110 μg route of administration: Respiratory experiment type: SINGLE co-administered: GLYCOPYRROLATE	GLYCOPYRROLATE	INDACATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.206 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg single, respiratory dose: 150 μg route of administration: Respiratory experiment type: SINGLE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.518 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg single, respiratory dose: 300 μg route of administration: Respiratory experiment type: SINGLE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.299 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.697 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2750 pg × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	110 μg 1 times / day steady-state, respiratory dose: 110 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: GLYCOPYRROLATE	GLYCOPYRROLATE	INDACATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
907 pg × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	110 μg single, respiratory dose: 110 μg route of administration: Respiratory experiment type: SINGLE co-administered: GLYCOPYRROLATE	GLYCOPYRROLATE	INDACATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.974 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg single, respiratory dose: 150 μg route of administration: Respiratory experiment type: SINGLE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.43 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg single, respiratory dose: 300 μg route of administration: Respiratory experiment type: SINGLE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.51 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.52 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
116 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
118 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	Disc. AE: Dyspnea, Wheezing... AEs leading to discontinuation/dose reduction: Dyspnea (serious, 1 patient) Wheezing (serious, 1 patient) Asthma (moderate, 1 patient) Cough (moderate, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
75 ug 1 times / day multiple, respiratory Dose: 75 ug, 1 times / day Route: respiratory Route: multiple Dose: 75 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf	unhealthy Health Status: unhealthy Condition: asthma Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf

AEs

AE	Significance	Dose	Population
Asthma	moderate, 1 patient Disc. AE	800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
Cough	moderate, 1 patient Disc. AE	800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
Dyspnea	serious, 1 patient Disc. AE	800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
Wheezing	serious, 1 patient Disc. AE	800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
Adverse event	grade 5	75 ug 1 times / day multiple, respiratory Dose: 75 ug, 1 times / day Route: respiratory Route: multiple Dose: 75 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf	unhealthy Health Status: unhealthy Condition: asthma Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	substrate 1037 inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2E1 882 CYP3A4/5 278 CYP1A2 1524 CYP2C8 911 CYP2C19 1478 P-gp 1461 MRP2 383 BCRP 699 hOCT1 10	UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A6 307 UGT1A8 283 UGT1A9 380 UGT1A10 291 UGT2B7 389 UGT2B15 203 CYP1A1 349 CYP1A2 1054 CYP1B1 92 CYP2A6 543 CYP2B6 664 CYP2C8 693 CYP2C18 138 CYP2C19 991 CYP2E1 667 CYP3A5 395 CYP4A11 119 P-gp 1537	P-gp 257 MRP2 111

Drug as perpetrator

Target	Modality	Activity
MRP2 475	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	negligible
P-gp 1650	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	negligible
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	no
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	no
BCRP 773	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	unlikely
MRP2 475	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	unlikely
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	unlikely
hOCT1 10	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	unlikely
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak [IC50 10 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak [IC50 25 uM]
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak [IC50 25 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak [IC50 5 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A5 395	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=98 Page: 98.0	likely
CYP1A1 349	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	low
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	low
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP1B1 92	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2A6 543	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2B6 664	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2C18 138	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2C8 693	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2E1 667	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP4A11 119	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A10 291	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A3 422	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A4 347	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A6 307	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A8 283	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A9 380	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT2B15 203	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT2B7 389	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak	yes (co-administration study) Comment: Co-administration of indacaterol with verapamil (P-gp inhibitor) showed 2 fold increase in indacaterol AUC0-24, and 1.5-fold increase in indacaterol Cmax; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0
UGT1A1 418	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	yes	weak (pharmacogenomic study) Comment: Nonsignificant trends toward higher Cmax and AUC0-24 (19% and 20%, respectively) were noted in patients with the (TA)7 genotype Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	yes	yes (co-administration study) Comment: Co-administration of indacaterol with erythromycin (CYP3A4 inhibitor) showed a 1.4-fold increase in indacaterol AUC0-24, and 1.2-fold increase in indacaterol Cmax; Co-administration of indacaterol with ketoconazole caused a 1.9-fold increase in indacaterol AUC0-24, and 1.3-fold increase in indacaterol Cmax; Co-administration of indacaterol with ritonavir resulted in a 1.7-fold increase in indacaterol AUC0-24 whereas indacaterol Cmax was unaffected. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000PharmR.pdf#page=46 Page: 46.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:68575	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:68575
ChemicalBook	CB72566367	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB72566367
ChemicalBook	CB82512068	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB82512068
MolPort	MolPort-023-219-171	https://www.molport.com/shop/molecule-link/MolPort-023-219-171
ZINC	ZINC000035801098	http://zinc15.docking.org/substances/ZINC000035801098

PubMed

Title	Date	PubMed
ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?	2007	17352511
Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.	2007 Dec	17999782
Gateways to clinical trials.	2008 Jan-Feb	18389098
A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.	2008 Jul	18479895
A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors.	2008 Nov-Dec	18652905
Gateways to clinical trials.	2009 Apr	19536362
Gateways to clinical trials.	2009 Sep	19907722
The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells.	2009 Sep	19371332
Impact of bronchodilator therapy on exercise tolerance in COPD.	2010 Apr 7	20463947
Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.	2010 Aug	20642373
Novel bronchodilators in asthma.	2010 Jan	19816179
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.	2010 Jun	20080201
Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.	2010 Sep	20567133
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone.	2010 Sep 7	20856830

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage of Indacaterol is the once-daily inhalation of the contents of one 75 mcg Indacaterol capsule using the NEOHALER inhaler.

Route of Administration: Respiratory

In Vitro Use Guide

In the isolated tracheal strip preparation, indacaterol, demonstrated concentration-dependent inhibition of electrically induced contraction (EC50= 45 ± 13 nM)

Substance Class	Chemical Created by `admin` on `Sat Dec 16 14:49:21 UTC 2023` Edited by `admin` on `Sat Dec 16 14:49:21 UTC 2023`
Record UNII	J3BI9P40XE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

INDACATEROL FUMARATE

Common Name

English

2(1H)-QUINOLINONE, 5-((1R)-2-((5,6-DIETHYL-2,3-DIHYDRO-1H-INDEN-2-YL)AMINO)-1-HYDROXYETHYL)-8-HYDROXY-, (2E)-2-BUTENEDIOATE (1:1)

Common Name

English

Code System Code Type Description

PUBCHEM

10255695

Created by admin on Sat Dec 16 14:49:21 UTC 2023 , Edited by admin on Sat Dec 16 14:49:21 UTC 2023

PRIMARY

SMS_ID

100000183718

Created by admin on Sat Dec 16 14:49:21 UTC 2023 , Edited by admin on Sat Dec 16 14:49:21 UTC 2023

PRIMARY

CAS

1000160-87-1

Created by admin on Sat Dec 16 14:49:21 UTC 2023 , Edited by admin on Sat Dec 16 14:49:21 UTC 2023

PRIMARY

FDA UNII

J3BI9P40XE

Created by admin on Sat Dec 16 14:49:21 UTC 2023 , Edited by admin on Sat Dec 16 14:49:21 UTC 2023

PRIMARY

Related Record Type Details


					8OR09251MQ

INDACATEROL

PARENT -> SALT/SOLVATE

Related Record Type Details


					8OR09251MQ

INDACATEROL

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf

C_max

T_1/2

Drug as perpetrator